D&D Pharmatech Inc. (KOSDAQ:347850)
86,900
-2,700 (-3.01%)
Jun 10, 2026, 3:30 PM KST
D&D Pharmatech Revenue
D&D Pharmatech had revenue of 128.78M KRW in the quarter ending March 31, 2026, a decrease of -90.89%. This brings the company's revenue in the last twelve months to 3.01B, down -71.91% year-over-year. In the year 2025, D&D Pharmatech had annual revenue of 4.30B, down -62.42%.
Revenue (ttm)
3.01B
Revenue Growth
-71.91%
P/S Ratio
1,302.67
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.92T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.30B | -7.14B | -62.42% |
| Dec 31, 2024 | 11.44B | -7.24B | -38.77% |
| Dec 31, 2023 | 18.68B | 18.07B | 2,958.97% |
| Dec 31, 2022 | 610.57M | -753.54M | -55.24% |
| Dec 31, 2021 | 1.36B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SK Biopharmaceuticals | 790.25B |
| SK bioscience | 665.42B |
| PharmaResearch | 565.48B |
| Hugel | 451.93B |
| LigaChem Biosciences | 125.87B |
| HLB Co., Ltd. | 85.20B |
| OliX Pharmaceuticals | 17.26B |
| Voronoi | 7.51B |